Goldman Sachs analysts removed Insmed (INSM) from the firm’s US Conviction List as part of its monthly update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed treatment of Duchenne muscular dystrophy granted orphan designation
- Insmed price target raised to $144 from $126 at Morgan Stanley
- Insmed’s Promising Future: Buy Rating Backed by Brinsupri Approval and Strategic Growth Prospects
- Insmed price target raised to $135 from $111 at JPMorgan
- Insmed initiated with an Outperform at William Blair